Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator Initiated Prospective Randomized Study of Radiofrequency Ablation, Chemoembolization, Radioembolization or Combination for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial).

Next Previous
Trial Profile

An Investigator Initiated Prospective Randomized Study of Radiofrequency Ablation, Chemoembolization, Radioembolization or Combination for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin; Doxorubicin; Mitomycin; Yttrium-90
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms PREMIERE

Most Recent Events

  • 13 Mar 2020 Biomarkers information updated
  • 19 Mar 2012 Planned number of patients changed from 258 to 124 as reported by ClinicalTrials.gov.
  • 02 Nov 2010 Planned end date changed from 1 Aug 2016 to 1 Aug 2018 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top